Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There are 2 clinical trials
This study will assess the safety and immunogenicity of AG0301-COVID19 in healthy adult volunteers.
Description: Frequency and severity of each adverse event, solicited local and systemic AEs 8 weeks after each vaccination
Measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Time: Week 1 through Week 9Description: Change in Geometric mean titer (GMT) of serum anti-SARS-CoV-2 spike (S) glycoprotein-specific antibody
Measure: Immunogenicity Time: Weeks 3, 5, 7, 9This study will assess the safety and immunogenicity of AG0301-COVID19 in healthy adult volunteers.
Description: Frequency and severity of each adverse event, solicited local and systemic AEs 8 weeks after each vaccination
Measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Time: Week 1 through Week 9Description: Change in Geometric mean titer (GMT) of serum anti-SARS-CoV-2 spike (S) glycoprotein-specific antibody
Measure: Immunogenicity Time: Weeks 3, 5, 7, 9Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports